TriangleDISEASE & TREATMENT SETTING
Gastric Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Gastric Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Gastric Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
17 more-specific settings
Trazimera: metastatic gastric cancer with HER2 stated without a specific alteration →OPDIVO QVANTIG: metastatic gastric cancer with PD-L1 stated without a specific alteration →Ontruzant: metastatic gastric cancer with HER2 stated without a specific alteration →OPDIVO: metastatic gastric cancer with PD-L1 stated without a specific alteration →TEVIMBRA: unresectable metastatic gastric cancer with HER2 negative, PD-L1 stated without a specific alteration (first-line) →Enhertu: metastatic gastric cancer with HER2 Positive, HER2 positive after prior therapy →Herceptin: metastatic gastric cancer with HER2 stated without a specific alteration →OGIVRI: metastatic gastric cancer with HER2 stated without a specific alteration →KEYTRUDA: unresectable metastatic gastric cancer with HER2 positive, PD-L1 stated without a specific alteration (first-line) →Kanjinti: metastatic gastric cancer with HER2 stated without a specific alteration →KEYTRUDA QLEX: unresectable metastatic gastric cancer with HER2 positive, PD-L1 stated without a specific alteration (first-line) →HERZUMA: metastatic gastric cancer with HER2 stated without a specific alteration →LONSURF: metastatic gastric cancer with HER2 stated without a specific alteration →CYRAMZA: metastatic gastric cancer after prior therapy →Stage 0 Gastric Cancer →Stage I Gastric Cancer →Stage IV recurrent Gastric Cancer →
Study evidence for this setting
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Bupropion in Helping Adults Stop Smoking
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Acceptability of Less Harmful Alternatives to Cigarettes
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Cancer in Patients With Gabapentin (GPRD)
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
HIPEC for Peritoneal Carcinomatosis
A Study of TAS-120 in Patients With Advanced Solid Tumors
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Fam
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-gastric-cancer
- binding id
- ncit-C4911
- source collection
- ncit-concept
- source key
- C4911
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-gastric-cancer
- binding id
- ncit-C9331
- source collection
- ncit-concept
- source key
- C9331
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice